Rules, not adviceThis page summarizes federal law and CMS guidance as published on the dates in the sources. Your own coverage is decided by your plan; its formulary and prior authorization form are the final word. We do not list coupons, savings cards or sellers.
Does insurance cover Zepbound? Coverage at a glance
Insurance covers Zepbound in some cases and not others: the payer and the prescribed use decide it.[3][8][2]
| Payer | Zepbound for weight loss | Zepbound for sleep apnea |
|---|---|---|
| Medicare Part D[1][7] | Excluded from basic coverage by law | Covered as a Part D drug |
| Medicare GLP-1 Bridge[8] | $50 a month, KwikPen only, if eligible (July 1, 2026 to December 31, 2027) | Not through the Bridge; goes to Part D |
| Medicaid[2][11] | Each state decides; some states may join the voluntary BALANCE Model | State drug rules; the optional exclusion names weight-loss use only |
| Employer and individual plans[12] | Plan by plan; self-insured employers must generally opt in | Plan by plan |
| Self-pay (no insurance)[15] | LillyDirect prices; vials are self-pay only | Same prices |
Self-pay prices per dose are worked out on Zepbound cost.
Does Medicare cover Zepbound?
Medicare Part D covers Zepbound when it is prescribed for moderate to severe obstructive sleep apnea in adults with obesity, but not for weight loss alone, except through the temporary GLP-1 Bridge.[7][8]
- The exclusion is in the statute. A covered Part D drug does not include drugs that may be excluded under section 1927(d)(2) of the Social Security Act, and that list includes “Agents when used for anorexia, weight loss, or weight gain.”[1][2]
- CMS's own summary: “Since the beginning of the Part D program in 2006, all drugs when used for weight loss have been excluded from basic coverage.”[3]
- Another approved use changes that. A weight-loss drug with FDA approval for an additional medically accepted indication “can be considered a Part D drug for that specific use.”[3]
- Sleep apnea qualifies. CMS told Part D plans in June 2026 that people prescribed Zepbound for moderate to severe obstructive sleep apnea in adults with obesity “should continue to receive coverage through Medicare Part D.”[7] The FDA approved that use on December 20, 2024.[16]
- The rule did not change. CMS proposed in December 2024 to let Part D cover anti-obesity drugs for obesity, then said in April 2025 that it was “not finalizing” that provision.[4][5]
CMS lists type 2 diabetes, moderate to severe sleep apnea and noncirrhotic MASH as uses of GLP-1 drugs that are eligible for Part D coverage.[8] Dosing for the sleep apnea use is on Zepbound for sleep apnea.
Does Medicare cover Mounjaro?
Medicare Part D plans can cover Mounjaro for type 2 diabetes, because CMS lists type 2 diabetes as a use of GLP-1 drugs eligible for Part D coverage; Mounjaro is not part of the GLP-1 Bridge.[8]
- Part D: coverage and the copay depend on the plan's formulary, and people with type 2 diabetes are routed to Part D rather than the Bridge.[8]
- Bridge: the Bridge list names Foundayo, Wegovy and the Zepbound KwikPen only.[8]
- Medicaid: all Mounjaro formulations are among the drugs in the voluntary BALANCE Model.[11]
Mounjaro's side effects and uses are on Mounjaro side effects.
The Medicare GLP-1 Bridge
The Medicare GLP-1 Bridge is a temporary CMS demonstration, running from July 1, 2026 to December 31, 2027, that lets eligible Part D enrollees get certain GLP-1 drugs for weight loss at “a predictable and affordable cost of $50 per month.”[9][6]
| Item | What CMS says |
|---|---|
| Dates[6][10] | July 1, 2026 to December 31, 2027 (extended through 2027 on April 21, 2026) |
| Your cost[9][7] | $50 per month, the same in every Part D benefit phase |
| Deductible and out-of-pocket total[6] | Part D deductible does not apply; the $50 does not count toward true out-of-pocket costs; no Extra Help (LIS) applies |
| Price paid to the maker[7] | $245 net per monthly supply |
| Zepbound covered[8] | KwikPen only (six NDCs, 2.5 to 15 mg) |
| Zepbound not covered[8] | Single-dose vials and single-dose pens; pen needles |
| Other drugs covered[8] | Wegovy (injection and tablets) and Foundayo, all formulations |
| Plans[8] | Standalone Part D plans and Medicare Advantage drug plans (HMO, PPO, SNPs, employer group plans) |
| Legal basis[6] | Section 402 demonstration authority, run outside the normal Part D benefit |
CMS is explicit about the device: “The single-dose vial and single-dose pen formulations of Zepbound® will not be available through the Medicare GLP-1 Bridge.”[8] How the KwikPen works is on Zepbound KwikPen.
Medicare GLP-1 Bridge criteria checker
CMS clinical criteria as published August 6, 2026
This checker needs JavaScript. The criteria are listed below it.
Formula. BMI = weight (kg) ÷ height (m)², or 703 × weight (lb) ÷ height (in)². The checker applies the published BMI and condition criteria only; it is not a coverage decision.
Who qualifies for the Bridge
To qualify, the prescription must be to reduce excess body weight and maintain weight reduction, with ongoing lifestyle changes, for an adult (18 or older) who met one of these at the start of GLP-1 treatment:[8]
- BMI of 35 or more; or
- BMI of 30 or more with heart failure with preserved ejection fraction, uncontrolled high blood pressure (above 140/90 despite two medicines) or chronic kidney disease stage 3a or worse; or
- BMI of 27 or more with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
The BMI test is applied at the start of GLP-1 treatment, not on the day of the request. CMS gives the example of someone who started in September 2024 at a BMI of 37 and had a BMI of 34 when the request was made in July 2026; that person qualifies.[8]
People with type 2 diabetes, moderate to severe sleep apnea or noncirrhotic MASH cannot use the Bridge; their GLP-1 goes through Part D instead. So does anyone eligible for GLP-1 coverage through Part D, “regardless of whether it is on the beneficiary's Part D plan's formulary.”[8][7]
Zepbound prior authorization
Zepbound coverage nearly always runs through a prior authorization: it is required for the Medicare GLP-1 Bridge, and CMS lets Part D plans use one to confirm the approved use.[8][3] Under the Bridge, the order is set by CMS:[8][6]
- The prescriber sends the prescription to the pharmacy.
- The pharmacy submits the claim to the Bridge, then sends the prior authorization request to the prescriber, electronically or by fax, typically within 24 to 72 hours. A request filed before any pharmacy claim exists comes back as “patient not found.”
- The prescriber attests that the clinical criteria are met. A Part D denial is not needed first.
- A single CMS central processor decides within 72 hours of submission.
- There is no appeal: “There is no appeals process under Medicare GLP-1 Bridge,” but the form can be sent again.
Commercial plans write their own prior authorization criteria, so the plan's own form is the reference. Stating the use (weight management or sleep apnea) on the prescription matters under every payer, because coverage follows the use.[3]
Does Medicaid cover Zepbound?
Medicaid coverage of Zepbound for weight loss is optional: federal law lets each state exclude drugs used for weight loss, so the answer depends on the state.[2] The statute says a state “may exclude or otherwise restrict coverage” of drugs on the section 1927(d)(2) list, which includes weight-loss agents.[2] CMS has described these drugs as “an optional drug benefit for Medicaid programs.”[4]
The CMS BALANCE Model adds a second route. It is voluntary for manufacturers, state Medicaid agencies and Part D plans, and CMS negotiates prices and coverage terms with GLP-1 makers on their behalf.[11]
| Part | Status |
|---|---|
| Medicaid[11][10] | States choose a start date between May 1, 2026 and January 1, 2027; applications closed July 31, 2026 |
| Medicare Part D[10] | Delayed: not launching for 2027 |
| Drugs[11] | All Mounjaro, Ozempic, Rybelsus and Wegovy formulations, the Zepbound KwikPen, and Foundayo |
| Guarantee[11] | “This model will not guarantee coverage for any individual.” |
CMS has not published which states joined, so a state Medicaid office or plan is the source for any individual answer.[11]
Does private insurance cover Zepbound?
Employer and individual plans decide for themselves; Lilly's 2025 annual report says that in the U.S., self-insured employers “must generally opt in for coverage of anti-obesity medicines.”[12] When Lilly launched the vials in 2024, it said the classification of obesity results in “many employers and the federal government excluding medications like Zepbound from insurance coverage.”[13]
Lilly sells Zepbound at self-pay prices for people without that coverage: the single-dose vials go through LillyDirect's self-pay channel, and the KwikPen is self-pay priced “for people without obesity management medicine insurance coverage.”[13][14] LillyDirect lists “Select insurance accepted” for the KwikPen.[15]
Which Zepbound form each program covers
Only the KwikPen appears in every program: the Bridge and BALANCE name it, and both leave out the single-dose vials and pens.[8][11] On LillyDirect, the vial is self-pay only and Lilly says the single-dose pen may be the lower-cost option for people whose commercial insurance covers it.[15]
| Presentation | Medicare GLP-1 Bridge | BALANCE Model | LillyDirect |
|---|---|---|---|
| KwikPen (4 doses) | Yes | Yes | Self-pay; select insurance accepted |
| Single-dose pen | No | Not listed | Listed; Lilly points insured patients to it |
| Single-dose vial | No | Not listed | Self-pay only |
| Multi-dose vial | Not listed | Not listed | Not listed |
All four presentations are compared on Zepbound pen vs vial.
Medicare and Medicaid coverage timeline
Federal coverage of weight-loss drugs has changed more since 2024 than in the previous 18 years.[3][6]
- Part D begins; drugs used for weight loss are excluded from basic coverage.[3]
- CMS: a weight-loss drug approved for another medically accepted use can be a Part D drug for that use.[3]
- CMS proposes Part D and Medicaid coverage of anti-obesity drugs.[4]
- FDA approves Zepbound for obstructive sleep apnea.[16]
- CMS does not finalize the anti-obesity drug proposal.[5]
- CMS announces the voluntary BALANCE Model.[17]
- Bridge drug list adds Foundayo and limits Zepbound to the KwikPen.[8]
- Bridge extended through 2027; BALANCE in Part D delayed.[10]
- Medicare GLP-1 Bridge starts at $50 a month.[9]
- Bridge running; Medicaid BALANCE start dates set by each joining state.[11]
- Bridge scheduled to end.[6]
Related
- Zepbound costSelf-pay prices per dose and per year
- Foundayo vs ZepboundThe other Lilly drug in the Bridge
- Generic ZepboundPatents, exclusivity and filings
Frequently asked questions
Does Medicare cover Zepbound for weight loss?
Does Medicare cover Zepbound for sleep apnea?
Yes. CMS says people prescribed Zepbound for moderate to severe obstructive sleep apnea in adults with obesity should keep getting coverage through Part D.[7]
Does the Medicare GLP-1 Bridge cover Zepbound vials?
No. Only the Zepbound KwikPen is covered; the single-dose vials and single-dose pens are not.[8]
Does Medicare cover the Zepbound KwikPen?
Does Medicare cover Mounjaro?
Part D plans can cover Mounjaro for type 2 diabetes, a use CMS lists as eligible for Part D; it is not on the GLP-1 Bridge list. Coverage and copay depend on the plan.[8]
Does Medicaid cover Zepbound?
How long does Zepbound prior authorization take?
Under the Medicare GLP-1 Bridge, decisions are sent within 72 hours of submission, and there is no appeal, though the form can be resubmitted. Commercial plans set their own timelines.[8]
Who qualifies for the Medicare GLP-1 Bridge?
Adults with Part D whose BMI at the start of treatment was 35 or more, or 30 or more with certain heart or kidney conditions, or 27 or more with prediabetes or past heart attack, stroke or artery disease, and who do not have type 2 diabetes, sleep apnea or MASH.[8]
Sources
- Social Security Act §1860D-2(e): definition of a covered Part D drug
- Social Security Act §1927(d): drugs a state may exclude or restrict
- HPMS memo: Part D coverage of anti-obesity medications with medically accepted indications
- Contract Year 2026 policy and technical changes (proposed rule, including Part D coverage of anti-obesity medications)
- Fact sheet: Contract Year 2026 final rule (CMS-4208-F)
- Medicare GLP-1 Bridge
- Medicare GLP-1 Bridge: expectations and frequently asked questions for Part D sponsors
- Medicare GLP-1 Bridge: information for providers
- CMS launches Medicare GLP-1 Bridge, expanding access to GLP-1 medications
- HPMS memo: status update on the Bridge demonstration and BALANCE Model in Part D for CY2027
- BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
- Eli Lilly and Company Form 10-K for fiscal year 2025
- Lilly releases Zepbound single-dose vials, expanding supply and access
- Media statement: Zepbound KwikPen now available at self-pay pricing at major pharmacies
- Zepbound on LillyDirect: formats and self-pay prices
- FDA approves first medication for obstructive sleep apnea
- CMS launches voluntary model to expand access to life-changing medicines, promote healthier living (BALANCE Model)